Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.

Zhang Y, Clarke W, Marzinke MA, Piwowar-Manning E, Beauchamp G, Breaud A, Hendrix CW, Cloherty GA, Emel L, Rose S, Hightow-Weidman L, Siegel M, Shoptaw S, Fields SD, Wheeler D, Eshleman SH.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02743-16. doi: 10.1128/AAC.02743-16. Print 2017 Jul.

PMID:
28438932
2.

Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study.

Roberts ST, Haberer J, Celum C, Mugo N, Ware NC, Cohen CR, Tappero JW, Kiarie J, Ronald A, Mujugira A, Tumwesigye E, Were E, Irungu E, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):313-322.

3.

Beyond informed consent: ethical considerations in the design and implementation of sexual and reproductive health research among adolescents.

Folayan MO, Haire B, Harrison A, Fatusi O, Brown B.

Afr J Reprod Health. 2014 Sep;18(3 Spec No):118-26.

4.

Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.

Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team.

Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538.

5.

Ethical Issues in Adolescents' Sexual and Reproductive Health Research in Nigeria.

Folayan MO, Haire B, Harrison A, Odetoyingbo M, Fatusi O, Brown B.

Dev World Bioeth. 2015 Dec;15(3):191-8. doi: 10.1111/dewb.12061. Epub 2014 Jun 9. Review.

6.

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8. doi: 10.1097/QAI.0000000000000172.

7.

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events.

Gervasoni C, Meraviglia P, Landonio S, Baldelli S, Fucile S, Castagnoli L, Clementi E, Riva A, Galli M, Rizzardini G, Cattaneo D.

PLoS One. 2013 Dec 2;8(12):e80242. doi: 10.1371/journal.pone.0080242. eCollection 2013.

8.

Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.

Baxi SM, Greenblatt RM, Bacchetti P, Scherzer R, Minkoff H, Huang Y, Anastos K, Cohen M, Gange SJ, Young M, Shlipak MG, Gandhi M.

AIDS. 2014 Jan 2;28(1):59-66. doi: 10.1097/QAD.0000000000000033.

9.

Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team.

Antimicrob Agents Chemother. 2013 Nov;57(11):5619-28. doi: 10.1128/AAC.01096-13. Epub 2013 Sep 3.

10.

Pharmacotherapy of pediatric HIV infection.

Rakhmanina N, Phelps BR.

Pediatr Clin North Am. 2012 Oct;59(5):1093-115. doi: 10.1016/j.pcl.2012.07.009. Epub 2012 Aug 22. Review.

11.

Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Baheti G, King JR, Acosta EP, Fletcher CV.

AIDS. 2013 Jan 14;27(2):221-5. doi: 10.1097/QAD.0b013e32835a9a2d.

12.

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM; iPrEx Study Team.

Sci Transl Med. 2012 Sep 12;4(151):151ra125.

13.

Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90. doi: 10.1089/AID.2012.0089. Epub 2012 Oct 10.

14.

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, Palma P, Bernardi S.

BMC Infect Dis. 2012 Jan 23;12:18. doi: 10.1186/1471-2334-12-18.

15.

Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team.

Clin Infect Dis. 2012 Apr;54(7):1013-25. doi: 10.1093/cid/cir968. Epub 2012 Jan 19.

16.

Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.

Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Honda M, Teruya K, Kikuchi Y, Oka S.

PLoS One. 2012;7(1):e29977. doi: 10.1371/journal.pone.0029977. Epub 2012 Jan 5.

17.

Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.

Baheti G, Kiser JJ, Havens PL, Fletcher CV.

Antimicrob Agents Chemother. 2011 Nov;55(11):5294-9. doi: 10.1128/AAC.05317-11. Epub 2011 Sep 6.

18.

Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S.

PLoS One. 2011;6(7):e22661. doi: 10.1371/journal.pone.0022661. Epub 2011 Jul 25.

19.

Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.

de Lastours V, Fonsart J, Burlacu R, Gourmel B, Molina JM.

Antimicrob Agents Chemother. 2011 Oct;55(10):4905-7. doi: 10.1128/AAC.00120-11. Epub 2011 Jul 25.

20.

Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.

Achenbach CJ, Darin KM, Murphy RL, Katlama C.

Future Virol. 2011 Feb;6(2):157-177.

Supplemental Content

Support Center